Bristol-Myers Squibb Stock Forum

See remaining FDA PDUFAs in May 👀👇
$Bristol-Myers Squibb(BMY.US)$ : Breyanzi
‣ PDUFA date: 5/31/24 (sBLA)
$Moderna(MRNA.US)$ : mRNA-1345
‣ PDUFA date: End of May 2024 (est.) (BLA)
📣 Buckle up & get ready for next month...
June brings 17 PDUFA decisions: 🔥 🔥
$Catalyst Pharmaceuticals(CPRX.US)$ : FIRDAPSE® (Amifampridine)
$GlaxoSmithKline(GSK.US)$ : Arexvy
$Genfit(GNFT.US)$ & $IPSEN SA SPONS ADR EA REPR 0.25 ORD(IPSEY.US)$ : Elafibranor
$Regeneron Pharmaceuticals(REGN.US)$ : Kevzara (sarilumab)
$Bristol-Myers Squibb(BMY.US)$ : Augtyro...

Clinical Updates💉
⇒ $Larimar Therapeutics(LRMR.US)$ 🟢
‣ FDA removes partial clinical hold
‣ Nomlabofusp (CTI-1601) #FA
‣ Protein replacement therapy
‣ Interim data from OLE in Q4 '24 🔔
Clinical readouts 📢
⇒ $Citius Pharmaceuticals(CTXR.US)$ 🟢
‣ Positive Ph3 topline results
‣ Mino-Lok® #CLABSI #CRBSI
‣ Antibiotic lock solution
‣ Overall treatment success in 57.1% patients
Regulatory Update🎯
⇒ $Halozyme Therapeutics(HALO.US)$ $Bristol-Myers Squibb(BMY.US)$
‣ FDA Reassigned PDUFA data to 12/29/24
‣ Subcutane...

📣 2 PDUFAs left in May!
🗓️ Last week’s PDUFAs:
$Amgen(AMGN.US)$ : Approved 5/16 🎉
⇒ Imdelltra (Tarlatamab-dlle)
‣ extensive-stage SCLC
‣ PDUFA date: 6/12/24 (BLA)
$Bristol-Myers Squibb(BMY.US)$ : Approved 5/15 🎉
⇒ Breyanzi®
‣ Follicular lymphoma
‣ PDUFA date: 5/23/24 (sBLAs)
$Dynavax Technologies(DVAX.US)$ : CRL 5/14 🙁
⚠️ insufficient data
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US)$ : Review extended to 8/14/24 🤔
⇒ YORV...

$Bristol-Myers Squibb(BMY.US)$ go up go up, you can do it

See summary 👇
📣 4 PDUFAs upcoming in May:
$Dynavax Technologies(DVAX.US)$ : 🤔
⇒ Heplisav-B
‣ vaccination of adults on hemodialysis
‣ PDUFA date: 5/13/24 (sBLA)
$Ascendis Pharma A/S(ASND.US)$ : 🤔
⇒ YORVIPATH®
‣ hypoparathyroidism
‣ PDUFA date: 5/14/24 (NDA)
$Bristol-Myers Squibb(BMY.US)$ : 🤔
⇒ Breyanzi®
‣ PDUFA dates: (sBLAs)
‣‣ 5/23/24 (r/r follicular lymphoma)
‣‣ 5/31/24 (r/r mantle cell lymphoma)
🗓️ Last week’s PDUFAs:
$X4 Pharmaceuticals(XFOR.US)$ : Approved 4/29 🎉
⇨ XOLREMDI (mavorixafor)
‣ WHI...

$Bristol-Myers Squibb(BMY.US)$ buy the dip, Will be go up again to 45 easily

Top 10 drug companies raked in NEARLY TRIPLE the revenue in 2023 ($491B) vs 2013 ($165B) 2013 vs. 2023.
$AbbVie(ABBV.US)$ +189%
$Bristol-Myers Squibb(BMY.US)$ +175%
$Johnson & Johnson(JNJ.US)$ +95%
$AstraZeneca(AZN.US)$ +78%
$NVM +45%
$Merck & Co(MRK.US)$ +37% 
$ROCHE HOLDING AG(RHHBY.US)$ +27%
$Pfizer(PFE.US)$ +13%
$GlaxoSmithKline(GSK.US)$ +13%
----- $SPDR S&P 500 ETF(SPY.US)$ +12% -----
$Sanofi(SNY.US)$ +3%
Source: Arjun Murthy on the HR app!

The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
$Pfizer(PFE.US)$ $Dynavax Technologies(DVAX.US)$ $Sandstorm Gold(SAND.US)$ $Bristol-Myers Squibb(BMY.US)$ $SPDR S&P Biotech ETF(XBI.US)$

$Bristol-Myers Squibb(BMY.US)$ Sold small lottery tickets yesterday with a plan to buy more $Rio Tinto Ltd(RIO.AU)$ today but instead I bought this turd on a whim.  Very upset with myself